| Literature DB >> 32325910 |
Michael F Criscitiello1,2, Igor Kraev3, Sigrun Lange4.
Abstract
The bovine immune system is known for its unusual traits relating to immunoglobulin and antiviral responses. Peptidylarginine deiminases (PADs) are phylogenetically conserved enzymes that cause post-translational deimination, contributing to protein moonlighting in health and disease. PADs also regulate extracellular vesicle (EV) release, forming a critical part of cellular communication. As PAD-mediated mechanisms in bovine immunology and physiology remain to be investigated, this study profiled deimination signatures in serum and serum-EVs in Bos taurus. Bos EVs were poly-dispersed in a 70-500 nm size range and showed differences in deiminated protein cargo, compared with whole sera. Key immune, metabolic and gene regulatory proteins were identified to be post-translationally deiminated with some overlapping hits in sera and EVs (e.g., immunoglobulins), while some were unique to either serum or serum-EVs (e.g., histones). Protein-protein interaction network analysis of deiminated proteins revealed KEGG pathways common for serum and serum-EVs, including complement and coagulation cascades, viral infection (enveloped viruses), viral myocarditis, bacterial and parasitic infections, autoimmune disease, immunodeficiency intestinal IgA production, B-cell receptor signalling, natural killer cell mediated cytotoxicity, platelet activation and hematopoiesis, alongside metabolic pathways including ferroptosis, vitamin digestion and absorption, cholesterol metabolism and mineral absorption. KEGG pathways specific to EVs related to HIF-1 signalling, oestrogen signalling and biosynthesis of amino acids. KEGG pathways specific for serum only, related to Epstein-Barr virus infection, transcription mis-regulation in cancer, bladder cancer, Rap1 signalling pathway, calcium signalling pathway and ECM-receptor interaction. This indicates differences in physiological and pathological pathways for deiminated proteins in serum-EVs, compared with serum. Our findings may shed light on pathways underlying a number of pathological and anti-pathogenic (viral, bacterial, parasitic) pathways, with putative translatable value to human pathologies, zoonotic diseases and development of therapies for infections, including anti-viral therapies.Entities:
Keywords: anti-viral; bovine (Bos taurus); extracellular vesicles (EVs); immunity; metabolism; peptidylarginine deiminases (PADs); protein deimination
Year: 2020 PMID: 32325910 PMCID: PMC7215346 DOI: 10.3390/ijms21082861
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Extracellular vesicle profiling in bovine serum. (A) Nanoparticle tracking analysis shows a size distribution of plasma-EVs from Bos taurus in the size range of 70 to 500 nm, with main peaks at approximately 120–240 nm. (B) Transmission electron microscopy (TEM) analysis of bovine serum-derived EVs shows typical EV morphology; scale bar is 50 nm in all figures. (C) Western blotting analysis confirms that bovine EVs are positive for the phylogenetically conserved EV-specific markers CD63 and Flot-1, showing positive at expected molecular weight size corresponding to what is observed in other taxa (kDa = kilodaltons).
Figure 2Deiminated proteins and peptidylarginine deiminases (PADs) in bovine serum. (A) Total deiminated proteins were identified in bovine serum using the pan-deimination specific F95 antibody. (B) F95-enriched IP fraction from bovine serum and serum-extracellular vesicles (EVs), shown by silver-staining. (C) Immunodetection of PAD homologues in bovine sera by western blotting, using anti-human PAD2, PAD3 and PAD4 antibodies. (D) A neighbor-joining phylogeny tree for bovine and human PAD isozymes.
Deiminated proteins in bovine serum (Bos taurus), as identified by F95-enrichment and LC-MS/MS analysis. Deiminated proteins from serum were isolated by immunoprecipitation using the pan-deimination F95 antibody. The resulting F95-enriched eluate was then analysed by LC-MS/MS and peak list files submitted to Mascot. Bos taurus species-specific peptide sequence hits are listed, showing number of sequences for protein hits and total score. Blue highlighted rows indicate protein hits identified in whole sera only. Uncharacterised proteins based on LC-MS/MS search were further confirmed in STRING, based on the protein symbol, and protein identification from STRING, where retrieved, is shown in brackets ([]). For further full LC-MS/MS analysis of all protein hits see Supplementary Table S1.
| Protein Name | Symbol | Sequences | Total Score ( |
|---|---|---|---|
| Serotransferrin | G3X6N3 | 76 | 5712 |
| Serotransferrin | Q29443 | 76 | 5711 |
| Complement factor H | Q28085 | 77 | 5123 |
| Alpha-2-macroglobulin | Q7SIH1 | 77 | 5079 |
| Serum albumin | A0A140T897 | 59 | 3944 |
| Uncharacterised protein [complement factor H] | F1MC45 | 54 | 3745 |
| Complement C3 | Q2UVX4 | 68 | 3483 |
| Uncharacterised protein [ceruloplasmin] | F1N076 | 44 | 2712 |
| Embryo-specific fibronectin 1 | B8Y9S9 | 37 | 2263 |
| Hemopexin | Q3SZV7 | 30 | 2019 |
| Uncharacterised protein [complement C4A] | E1BH06 | 34 | 1997 |
| C4b-binding protein alpha chain | Q28065 | 33 | 1841 |
| Kininogen-1 | A0A140T8C8 | 23 | 1505 |
| Kininogen-1 | P01044 | 22 | 1449 |
| Histidine-rich glycoprotein | F1MKS5 | 26 | 1432 |
| Uncharacterised protein (uncharacterised) | F1MJK3 | 26 | 1291 |
| Kininogen-2 | P01045 | 19 | 1271 |
| Uncharacterised protein (uncharacterised) | G3X7F3 | 16 | 1259 |
| Uncharacterised protein (uncharacterised) | G3N0V0 | 19 | 1186 |
| Apolipoprotein A-I preproprotein | V6F9A2 | 19 | 1122 |
| Uncharacterised protein (uncharacterised) | F1MVK1 | 17 | 953 |
| SERPIND1 protein | A6QPP2 | 16 | 865 |
| Uncharacterised protein (uncharacterised) | F1MZ96 | 13 | 837 |
| Uncharacterised protein [ | F1MLW7 | 10 | 815 |
| Uncharacterised protein [ | F1MCF8 | 10 | 796 |
| Uncharacterised protein [Immunoglobulin heavy constant mu] | G5E5T5 | 12 | 784 |
| Uncharacterised protein [Immunoglobulin heavy constant mu] | G5E513 | 10 | 732 |
| Uncharacterised protein (uncharacterised) | G3N0S9 | 12 | 648 |
| Histidine-rich glycoprotein | P33433 | 12 | 623 |
| Alpha-2-antiplasmin | P28800 | 11 | 531 |
| Uncharacterised protein (uncharacterised) | F1MLW8 | 5 | 434 |
| Hemoglobin subunit beta | P02070 | 6 | 422 |
| Vitamin D-binding protein | F1N5M2 | 9 | 420 |
| Alpha-1-antiproteinase | P34955 | 8 | 418 |
| Adiponectin | Q3Y5Z3 | 6 | 411 |
| Uncharacterised protein (uncharacterised) | F1MW79 | 7 | 403 |
| ECM1 protein | A5PJT7 | 8 | 395 |
| Complement C1q subcomponent subunit B | Q2KIV9 | 8 | 390 |
| Plasma kallikrein | Q2KJ63 | 8 | 385 |
| Inter-alpha-trypsin inhibitor heavy chain H4 | F1MMD7 | 6 | 367 |
| C1QC protein | Q1RMH5 | 5 | 347 |
| Uncharacterised protein [Serpin A3-5; Serine protease inhibitor] | G8JKW7 | 6 | 338 |
| Apolipoprotein A-IV | F1N3Q7 | 7 | 338 |
| Inter-alpha-trypsin inhibitor heavy chain H2 | F1MNW4 | 6 | 338 |
| Selenoprotein P | P49907 | 6 | 323 |
| Plasminogen | E1B726 | 6 | 302 |
| Complement C1q subcomponent subunit A | Q5E9E3 | 5 | 300 |
| Uncharacterised protein [ | F1MJZ4 | 6 | 277 |
| Thrombospondin-1 | F1N3A1 | 7 | 273 |
| Serpin A3-3 | G3N1U4 | 5 | 271 |
| Protein HP-20 homolog | Q2KIT0 | 5 | 269 |
| Uncharacterised protein (uncharacterised) | G5E604 | 4 | 234 |
| Inter-alpha-trypsin inhibitor heavy chain H1 | Q0VCM5 | 4 | 234 |
| Uncharacterised protein (uncharacterised) | E1B805 | 5 | 232 |
| Uncharacterised protein (uncharacterised) | G3MXD9 | 3 | 209 |
| Uncharacterised protein [ | G3N2D7 | 3 | 204 |
| Keratin, type II cytoskeletal 7 | Q29S21 | 4 | 199 |
| Keratin, type I cytoskeletal 14 | F1MC11 | 4 | 199 |
| Uncharacterised protein [Heparan sulfate proteoglycan 2] | F1MER7 | 4 | 195 |
| Alpha-2-HS-glycoprotein | cRAPR1|FETUA_BOVIN | 4 | 190 |
| Uncharacterised protein (uncharacterised) | G3N1H5 | 2 | 187 |
| Serpin A3-8 | A0A0A0MP89 | 3 | 184 |
| Complement factor B | P81187 | 4 | 183 |
| Protein AMBP | F1MMK9 | 5 | 181 |
| Serpin A3-2 | A2I7M9 | 4 | 180 |
| Antithrombin-III | F1MSZ6 | 5 | 176 |
| Paraoxonase 1 | Q2KIW1 | 4 | 174 |
| Gelsolin | F1MJH1 | 3 | 171 |
| Uncharacterised protein (uncharacterised) | G3N3Q3 | 2 | 168 |
| Complement C5a anaphylatoxin | F1MY85 | 3 | 166 |
| Uncharacterised protein (uncharacterised) | G5E5H2 | 3 | 162 |
| Serpin A3-7 | A0A0A0MP92 | 4 | 160 |
| C1QTNF3 protein | A7MB82 | 3 | 160 |
| Uncharacterised protein [ | E1BI82 | 4 | 157 |
| Uncharacterised protein [Apolipoprotein B] | E1BNR0 | 4 | 150 |
| Primary amine oxidase, liver isozyme | Q29437 | 3 | 137 |
| Coagulation factor XI | F1MUT4 | 2 | 127 |
| Hepatocyte growth factor-like protein | E1BDW7 | 2 | 121 |
| Fibrinogen beta chain | F1MAV0 | 3 | 108 |
| Immunoglobulin J chain | Q3SYR8 | 2 | 107 |
| Uncharacterised protein (uncharacterised) | G3MXB5 | 2 | 100 |
| Uncharacterised protein [CD5 molecule-like] | F1N514 | 2 | 94 |
| Uncharacterised protein (uncharacterised) | G3MXG6 | 2 | 94 |
| Complement component C9 | Q3MHN2 | 2 | 87 |
| Complement component C6 | F1MM86 | 3 | 86 |
| Uncharacterised protein (uncharacterised) | G5E5V1 | 2 | 86 |
| Hemoglobin subunit alpha | P01966 | 2 | 85 |
| Uncharacterised protein (uncharacterised) | G3N028 | 2 | 75 |
| Fibrinogen alpha chain | A5PJE3 | 1 | 74 |
| Vitronectin | Q3ZBS7 | 2 | 73 |
| Alpha-1B-glycoprotein | Q2KJF1 | 1 | 66 |
| Coagulation factor XII | F1MTT3 | 1 | 65 |
| Uncharacterised protein (uncharacterised) | F1MSF0 | 2 | 63 |
| Prothrombin | P00735 | 1 | 61 |
| Uncharacterised protein [Nidogen 1] | F1MWN3 | 1 | 57 |
| Protein HP-25 homolog 2 | Q2KIU3 | 1 | 57 |
| Clusterin | F1MWI1 | 1 | 55 |
| Contactin-1 | F1MVI0 | 1 | 54 |
| Polymeric immunoglobulin receptor | F1MR22 | 2 | 51 |
| Uncharacterised protein [Sperm associated antigen 9] | F1MZ69 | 2 | 51 |
| Uncharacterised protein [Ankyrin repeat domain 11] | E1BAT5 | 2 | 51 |
| Beta-2-glycoprotein 1 | A0A140T843 | 1 | 50 |
| Carboxypeptidase N catalytic chain | Q2KJ83 | 1 | 49 |
| Uncharacterised protein [complement component 8, alpha polypeptide (C8A)] | F1MX87 | 1 | 48 |
| Fibrinogen gamma-B chain | F1MGU7 | 1 | 48 |
| Uncharacterised protein [ADAM metallopeptidase with thrombospondin type 1 motif, 13] | F1MVP0 | 1 | 47 |
| Uncharacterised protein [Talin 1] | F1MDH3 | 1 | 46 |
| Complement C1s subcomponent | Q0VCX1 | 1 | 46 |
| Uncharacterised protein [CL43—Collectin-43] | F1MFY6 | 1 | 45 |
| Complement component C7 | F1N045 | 1 | 44 |
| CLEC11A protein | A5D7L1 | 1 | 43 |
| Uncharacterised protein [KCTD12—Potassium channel tetramerization domain containing 12] | G3N3D4 | 1 | 43 |
| Uncharacterised protein [BRIP1—BRCA1 interacting protein C-terminal helicase 1] | E1BNG9 | 1 | 39 |
| Cadherin-1 | F1N619 | 1 | 39 |
| Ubiquitin carboxyl-terminal hydrolase isozyme L5 | Q9XSJ0 | 1 | 38 |
| CPN2 protein | A6QP30 | 1 | 37 |
| Acyl-coenzyme A thioesterase THEM4 | A1A4L1 | 1 | 37 |
| Uncharacterised protein [SLAMF9—SLAM family member 9] | E1BNF9 | 1 | 36 |
| Uncharacterised protein [MED12; Mediator complex subunit 12] | F1MZ95 | 1 | 35 |
| Transthyretin | O46375 | 1 | 33 |
| Voltage-dependent L-type calcium channel subunit beta-3 | Q9MZL3 | 1 | 33 |
1 Ions score is −10*Log(P), where P is the probability that the observed match is a random event. Individual ions scores > 31 indicated identity or extensive homology (p < 0.05). Protein scores were derived from ions scores as a non-probabilistic basis for ranking protein hits.
Deiminated proteins in serum-EVs of cow (Bos taurus) as identified by F95-enrichment. Deiminated proteins from serum-EVs were isolated by immunoprecipitation using the pan-deimination F95 antibody. The resulting F95-enriched eluate was then analysed by LC-MS/MS and peak list files submitted to Mascot. Bos taurus species-specific peptide sequence hits are listed, showing number of sequences for protein hits and total score. Rows highlighted in pink indicate protein hits identified in serum-EVs only. Uncharacterised proteins based on LC-MS/MS search were further confirmed in STRING, based on the protein symbol, and protein identification from STRING, where retrieved, is shown in brackets ([]).For further full LC-MS/MS analysis of all protein hits see Supplementary Table S2.
| Protein Name | Symbol | Sequences | Total Score ( |
|---|---|---|---|
| Serotransferrin | G3X6N3 | 75 | 4958 |
| Serotransferrin | Q29443 | 74 | 4941 |
| Complement factor H | Q28085 | 85 | 4700 |
| Alpha-2-macroglobulin | Q7SIH1 | 77 | 4633 |
| Serum albumin | A0A140T897 | 76 | 4604 |
| Complement C3 | Q2UVX4 | 83 | 4258 |
| Uncharacterised protein (CFH—Complement factor H) | F1MC45 | 61 | 3469 |
| Fibronectin | G5E5A9 | 56 | 2492 |
| Uncharacterised protein (Ceruloplasmin) | F1N076 | 37 | 1994 |
| Uncharacterised protein (uncharacterised) | F1MJK3 | 38 | 1870 |
| Uncharacterised protein (C4A—Complement C4) | E1BH06 | 35 | 1840 |
| C4b-binding protein alpha chain | Q28065 | 36 | 1761 |
| Keratin, type II cytoskeletal 5 | M0QVZ6 | 35 | 1750 |
| Hemopexin | Q3SZV7 | 30 | 1594 |
| Keratin, type I cytoskeletal 14 | F1MC11 | 29 | 1592 |
| Uncharacterised protein (uncharacterised) | G3N0V0 | 25 | 1542 |
| Histidine-rich glycoprotein | F1MKS5 | 26 | 1407 |
| Uncharacterised protein (keratin 33A (KRT33A)) | F1MXG6 | 22 | 1311 |
| KRT33A protein | A5PJJ1 | 22 | 1306 |
| Keratin 31 | Q148I8 | 22 | 1291 |
| Uncharacterised protein (uncharacterised) | G3X7F3 | 20 | 1288 |
| Keratin, type II cuticular Hb1 | Q148H4 | 25 | 1225 |
| Uncharacterised protein (keratin 34 (KRT34)) | F1MSA6 | 21 | 1209 |
| Kininogen-1 | A0A140T8C8 | 21 | 1188 |
| Kininogen-1 | P01044 | 21 | 1164 |
| Uncharacterised protein (Desmoplakin) | E1BKT9 | 27 | 1156 |
| Uncharacterised protein (keratin 86 (KRT86)) | E1B898 | 22 | 1104 |
| Apolipoprotein A-I preproprotein | V6F9A2 | 22 | 1101 |
| Uncharacterised protein (uncharacterised) | F1MVK1 | 20 | 1066 |
| Uncharacterised protein (KRT6A—Keratin, type II cytoskeletal 59 kDa, component IV) | M0QVY0 | 21 | 1049 |
| Kininogen-2 | P01045 | 19 | 1042 |
| Uncharacterised protein (KRT3—Keratin, type II cytoskeletal 68 kDa, component IB) | G3MXL3 | 21 | 1034 |
| Junction plakoglobin | Q8SPJ1 | 21 | 987 |
| Keratin, type II cytoskeletal | Q08D91 | 19 | 971 |
| Uncharacterised protein (Immunoglobulin heavy constant mu) | G5E5T5 | 16 | 938 |
| Keratin, type I cytoskeletal 17 | A0A140T867 | 17 | 890 |
| Uncharacterised protein (IGLL1—immunoglobulin lambda-like polypeptide 1) | F1MCF8 | 12 | 886 |
| Uncharacterised protein (uncharacterised) | F1MH40 | 13 | 872 |
| Uncharacterised protein (uncharacterised) | F1MZ96 | 14 | 863 |
| Keratin 10 (Epidermolytic hyperkeratosis; keratosis palmaris et plantaris) | A6QNZ7 | 15 | 854 |
| Uncharacterised protein (uncharacterised) | F1MLW7 | 10 | 849 |
| Complement C4 | P01030 | 16 | 826 |
| Uncharacterised protein (Immunoglobulin heavy constant mu) | G5E513 | 15 | 810 |
| KRT15 protein | Q17QL7 | 13 | 734 |
| Uncharacterised protein (uncharacterised) | G3N0S9 | 14 | 631 |
| Keratin, type I cytoskeletal 19 | P08728 | 12 | 625 |
| KRT4 protein | A4IFP2 | 12 | 623 |
| SERPIND1 protein | A6QPP2 | 12 | 606 |
| Uncharacterised protein (uncharacterised) | F1MLW8 | 7 | 588 |
| Histidine-rich glycoprotein | P33433 | 9 | 566 |
| Inter-alpha-trypsin inhibitor heavy chain H2 | F1MNW4 | 12 | 554 |
| Inter-alpha-trypsin inhibitor heavy chain H4 | F1MMD7 | 10 | 521 |
| Vitamin D-binding protein | F1N5M2 | 12 | 517 |
| Antithrombin-III | F1MSZ6 | 11 | 492 |
| Plasminogen | P06868 | 14 | 485 |
| Apolipoprotein A-IV | Q32PJ2 | 11 | 475 |
| Serpin A3-3 | G3N1U4 | 9 | 442 |
| Complement factor B | P81187 | 9 | 429 |
| C1QC protein | Q1RMH5 | 8 | 428 |
| Complement C1q subcomponent subunit B | Q2KIV9 | 7 | 413 |
| Uncharacterised protein (serotransferrin-like) | E1BI82 | 8 | 411 |
| Uncharacterised protein (KRT16—Keratin 16) | G3X7W8 | 9 | 407 |
| Complement C1q subcomponent subunit A | Q5E9E3 | 7 | 401 |
| Serpin A3-4 | A2I7N0 | 9 | 383 |
| Alpha-1B-glycoprotein | Q2KJF1 | 7 | 381 |
| Uncharacterised protein (uncharacterised) | G3N3Q3 | 5 | 367 |
| Uncharacterised protein (Serpin A3-5) | G8JKW7 | 7 | 366 |
| Keratin, type II cytoskeletal 78 | A6QNX5 | 7 | 356 |
| Primary amine oxidase, liver isozyme | Q29437 | 8 | 352 |
| Serpin A3-2 | A2I7M9 | 7 | 333 |
| Uncharacterised protein (uncharacterised) | F1MW79 | 6 | 330 |
| Uncharacterised protein (uncharacterised) | G3N1H5 | 5 | 325 |
| Uncharacterised protein (KRT77—Keratin 77) | G3MYU2 | 6 | 310 |
| Uncharacterised protein (uncharacterised) | E1B805 | 7 | 309 |
| Uncharacterised protein (uncharacterised) | G3MXG6 | 4 | 305 |
| Uncharacterised protein (uncharacterised) | G3MXD9 | 5 | 300 |
| Uncharacterised protein (uncharacterised) | G3N2P6 | 5 | 292 |
| Uncharacterised protein (insulin-like growth factor binding protein, acid labile subunit (IGFALS)) | F1MJZ4 | 5 | 286 |
| Adiponectin | Q3Y5Z3 | 5 | 282 |
| Alpha-2-antiplasmin | P28800 | 7 | 271 |
| Protein AMBP | F1MMK9 | 6 | 268 |
| Vitronectin | Q3ZBS7 | 5 | 264 |
| Uncharacterised protein (uncharacterised) | G5E604 | 5 | 254 |
| Desmoglein-1 | F1MIW8 | 7 | 252 |
| Fibrinogen gamma-B chain | F1MGU7 | 5 | 252 |
| Uncharacterised protein (uncharacterised) | G3MY71 | 5 | 251 |
| Annexin A2 | P04272 | 5 | 244 |
| Fibrinogen alpha chain | A5PJE3 | 5 | 243 |
| Uncharacterised protein (uncharacterised) | G3MWT1 | 3 | 241 |
| Glyceraldehyde-3-phosphate dehydrogenase | P10096 | 6 | 238 |
| Serpin A3-7 | A0A0A0MP92 | 5 | 218 |
| Plakophilin-1 | Q28161 | 4 | 216 |
| Inter-alpha-trypsin inhibitor heavy chain H1 | Q0VCM5 | 5 | 213 |
| Hemoglobin subunit beta | P02070 | 4 | 212 |
| Alpha-1-antiproteinase | P34955 | 4 | 209 |
| Keratin, type II | A0JND2 | 4 | 198 |
| Actin, cytoplasmic 1 | F1MRD0 | 5 | 197 |
| Keratin, type I cytoskeletal 28 | Q148H6 | 4 | 194 |
| Thrombospondin-1 | F1N3A1 | 6 | 192 |
| Keratin, type I cytoskeletal 20 | F1MPK1 | 4 | 191 |
| ECM1 protein | A5PJT7 | 5 | 188 |
| Uncharacterised protein ( | G3N2D7 | 3 | 186 |
| Selenoprotein P | P49907 | 5 | 184 |
| Uncharacterised protein (uncharacterised) | A0A0A0MPA0 | 4 | 176 |
| Gelsolin | F1MJH1 | 4 | 175 |
| Lactotransferrin | P24627 | 4 | 169 |
| Fibrinogen beta chain | F1MAV0 | 5 | 162 |
| Uncharacterised protein (uncharacterised) | G5E5H2 | 3 | 156 |
| Protein HP-20 homolog | Q2KIT0 | 3 | 151 |
| Uncharacterised protein (TGM1—Transglutaminase 1) | F1MBB7 | 2 | 143 |
| Actin, gamma-enteric smooth muscle | F1MKC4 | 4 | 143 |
| Uncharacterised protein (CD5L—CD5 molecule-like) | F1N514 | 4 | 131 |
| Complement component C7 | F1N045 | 4 | 128 |
| Uncharacterised protein (APOB—Apolipoprotein B) | E1BNR0 | 4 | 119 |
| Arginase-1 | Q2KJ64 | 3 | 119 |
| Alpha-S1-casein | CASA1_BOVIN | 2 | 115 |
| Uncharacterised protein (uncharacterised) | G3N028 | 2 | 114 |
| Alpha-2-HS-glycoprotein | cRAPR1|FETUA_BOVIN | 2 | 106 |
| Paraoxonase 1 | Q2KIW1 | 3 | 106 |
| Beta-2-glycoprotein 1 | A0A140T843 | 2 | 97 |
| Uncharacterised protein (uncharacterised) | G5E5V1 | 2 | 89 |
| Uncharacterised protein (Histone H2B family) | E1B7N8 | 2 | 88 |
| Complement component 1, r subcomponent | A5D9E9 | 3 | 83 |
| Histone H2A | A0A0A0MP90 | 2 | 80 |
| Uncharacterised protein (SLK-STE20-like kinase) | G3X696 | 3 | 80 |
| Prothrombin | P00735 | 2 | 79 |
| Peroxiredoxin-2 | Q9BGI3 | 3 | 79 |
| Uncharacterised protein (uncharacterised) | G3MZE0 | 1 | 69 |
| Uncharacterised protein (complement component 8, alpha polypeptide (C8A)) | F1MX87 | 1 | 69 |
| Uncharacterised protein (C1orf68—Chromosome 1 open reading frame 68) | G3N3D3 | 2 | 68 |
| Complement C5a anaphylatoxin | F1MY85 | 2 | 63 |
| Uncharacterised protein (complement factor I (CFI)) | F1N4M7 | 1 | 61 |
| Uncharacterised protein (armadillo repeat gene deleted in velocardiofacial syndrome (ARVCF)) | E1BPV1 | 2 | 59 |
| Uncharacterised protein (NEK10-Uncharacterised protein; NIMA-related kinase 10) | E1BHZ1 | 2 | 58 |
| Keratin associated protein 13-1 | A1A4M9 | 2 | 57 |
| Uncharacterised protein (uncharacterised) | F1MSF0 | 2 | 57 |
| Histone H4 | E1B9M9 | 1 | 56 |
| Gamma-glutamylcyclotransferase | Q32LE4 | 1 | 55 |
| Uncharacterised protein (JAKMIP2—Janus kinase and microtubule interacting protein 2) | G5E551 | 2 | 54 |
| TOX high mobility group box family member 4 | Q0P5K4 | 1 | 53 |
| Uncharacterised protein (TBC1D32—TBC1 domain family, member 32) | F1N7V1 | 2 | 51 |
| Proteasome subunit alpha type-6 | Q2YDE4 | 1 | 50 |
| Uncharacterised protein (KIAA1009 ortholog) | F1MZ01 | 2 | 50 |
| Uncharacterised protein (MYO5B—Myosin VB) | F1MMQ6 | 2 | 50 |
| Uncharacterised protein (Phospholipid phosphatase related 4) | F1MJ26 | 2 | 49 |
| Uncharacterised protein (MGA—MGA, MAX dimerization protein) | E1BKB7 | 2 | 49 |
| Uncharacterised protein (GOLGB1—Golgin B1) | E1BKZ5 | 2 | 47 |
| Histone H3 | E1BGN3 | 1 | 46 |
| Uncharacterised protein (CROCC—Ciliary rootlet coiled-coil, rootletin) | E1BBS9 | 3 | 46 |
| Protein FAM149B1 | A0JNF3 | 2 | 45 |
| Alpha-enolase | F1MB08 | 2 | 45 |
| Uncharacterised protein (UBR4—Ubiquitin protein ligase E3 component n-recognin 4) | E1BHT5 | 3 | 45 |
| Complement component C9 | Q3MHN2 | 1 | 44 |
| Uncharacterised protein (DOCK8— | E1BNA6 | 2 | 44 |
| Uncharacterised protein (KPRP—Keratinocyte proline-rich protein) | E1BLN6 | 1 | 44 |
| Uncharacterised protein (CCDC14—Coiled-coil domain containing 14) | F1MS02 | 2 | 43 |
| Uncharacterised protein (Strawberry notch homolog 1(Drosophila)) | E1BMP8 | 3 | 42 |
| DNA-directed RNA polymerase subunit beta | A5PJW8 | 1 | 42 |
| Uncharacterised protein (CRYGN-Crystallin, gamma N) | E1BDQ1 | 1 | 42 |
| Flotillin-1 | Q08DN8 | 1 | 41 |
| Uncharacterised protein (SMG6—Uncharacterised protein; | E1BFK4 | 2 | 41 |
| C1QTNF3 protein | A7MB82 | 1 | 41 |
| Uncharacterised protein (Protocadherin gamma subfamily B, 1) | F1MCA2 | 1 | 40 |
| Uncharacterised protein (Death-associated protein kinase 1) | F1MRL0 | 1 | 39 |
| Acyl-coenzyme A thioesterase THEM4 | A1A4L1 | 1 | 37 |
| Uncharacterised protein (Centrosomal protein 104kDa) | E1BND2 | 1 | 37 |
| C8G protein | A8YXZ2 | 1 | 36 |
| Uncharacterised protein (SERPINB12—Serpin family B member 12) | E1BDF5 | 1 | 36 |
| Uncharacterised protein (SLAMF9 SLAM family member 9) | E1BNF9 | 1 | 36 |
| Complement C1s subcomponent | Q0VCX1 | 1 | 36 |
| Uncharacterised protein (methyltransferase like 3 (METTL3)) | F1MX80 | 1 | 35 |
| Uncharacterised protein (SPAG9—Sperm associated antigen 9) | F1MZ69 | 1 | 35 |
| Adenosylhomocysteinase | Q3MHL4 | 1 | 35 |
| Uncharacterised protein (HIVEP3—Human immunodeficiency virus type I enhancer binding protein 3) | F1MBK6 | 1 | 34 |
| Coagulation factor V | F1N0I3 | 1 | 33 |
| Uncharacterised protein (VPREB1—Uncharacterised protein) | F1N160 | 1 | 33 |
| Uncharacterised protein (SERPING1) | E1BMJ0 | 1 | 33 |
| PPARD protein | A4IFL4 | 32 | |
| Uncharacterised protein | F1MZ93 | 1 | 32 |
| Uncharacterised protein (NCBP1—Nuclear cap binding protein subunit 1) | E1BMM0 | 1 | 32 |
| Transthyretin | O46375 | 1 | 32 |
| Uncharacterised protein (Cryptochrome-1) | F1MXB2 | 1 | 32 |
| Tubulin alpha chain | F1MNF8 | 1 | 31 |
Ions score is −10*Log(P), where P is the probability that the observed match is a random event. Individual ions scores > 31 indicated identity or extensive homology (p < 0.05). Protein scores were derived from ions scores as a non-probabilistic basis for ranking protein hits.
Figure 3Deiminated proteins identified in bovine serum and serum-EVs. (A) Species specific hits identified for deiminated proteins in bovine serum (Table 1) and serum-EVs (Table 2) respectively, as well as number of overlapping hits are presented. (B) KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways identified to be enriched in deiminated proteins in bovine serum and serum-EVs respectively, as well as number of overlapping KEGG pathways, are presented. For specific KEGG pathways presented in the Venn diagram, see the protein–protein interaction networks in Figure 4, Figure 5, Figure 6, Figure 7 and Figure 8.
Figure 4Protein–protein interaction networks show all deiminated proteins which were identified in bovine serum. Protein–protein interactions were reconstructed based on both known and predicted interactions in serum of Bos taurus, using STRING analysis. (A) Query proteins are indicated by the coloured nodes represent and first shell of interactors. (B) KEGG pathways relating to the identified proteins and reported in STRING and relating to infection are highlighted (see colour code included in the figure). (C). KEGG pathways relating to the identified proteins and reported in STRING are highlighted for immunity (see colour code included in the figure). (D). KEGG pathways relating to cancer and disease for deiminated proteins identified are highlighted (see colour code included in the figure). (E). KEEG pathways relating to metabolism for deiminated proteins identified are highlighted (see the colour code included in the figure). The coloured lines highlight which protein interactions are identified through known interactions (this refers to curated databases, experimentally determined), through predicted interactions (this refers to gene neighborhood, gene fusion, gene co-occurrence) or through co-expression, text mining or protein homology (the colour key for connective lines is included in the figure).
Figure 5Protein–protein interaction networks of deiminated protein candidates identified in bovine serum only (not identified in EVs). Protein–protein interactions were reconstructed based on both known and predicted interactions by STRING analysis. (A) Query proteins are indicated by the coloured nodes and represent the first shell of interactors. (B) KEGG pathways reported in STRING and related to the identified proteins are highlighted (see the colour code included in the figure). The coloured lines highlight which protein interactions are identified through known interactions (this refers to curated databases, experimentally determined), through predicted interactions (this refers to gene neighborhood, gene fusion, gene co-occurrence) or through co-expression, text mining or protein homology (the colour key for connective lines is included in the figure).
Figure 6Protein–protein interaction networks of all deiminated proteins identified in serum-EVs of Bos taurus. Protein–protein interactions were reconstructed based on both known and predicted interactions by STRING analysis. (A) Query proteins are indicated by the coloured nodes and represent the first shell of interactors. (B) KEGG pathways reported in STRING and relating to infection are highlighted (see colour code included in the figure). (C) KEGG pathways relating to the identified proteins and reported in STRING are highlighted for other pathways (see colour code included in the figure). The coloured lines highlight which protein interactions are identified through known interactions (this refers to curated databases, experimentally determined), through predicted interactions (this refers to gene neighborhood, gene fusion, gene co-occurrence) or through co-expression, text mining or protein homology (the colour key for connective lines is included in the figure).
Figure 7Protein–protein interaction networks of deiminated protein candidates identified in bovine serum-EVs only (not identified in total serum). Protein–protein interactions were reconstructed based on both known and predicted interactions by STRING analysis. (A) Query proteins are indicated by the coloured nodes and represent the first shell of interactors. (B) KEEG pathways relating to the identified deiminated proteins and reported in STRING are highlighted (see colour code included in the figure). The coloured lines highlight which protein interactions are identified through known interactions (this refers to curated databases, experimentally determined), through predicted interactions (this refers to gene neighborhood, gene fusion, gene co-occurrence) or through co-expression, text mining or protein homology (the colour key for connective lines is included in the figure).
Figure 8Protein–protein interaction networks for common deiminated protein candidates identified in bovine serum and serum-EVs (excluding serum-specific or EV specific candidates). Protein–protein interactions were reconstructed based on both known and predicted interactions by STRING analysis. (A) Query proteins are indicated by the coloured nodes and represent the first shell of interactors. (B) KEGG pathways for to the identified deiminated proteins and reported in STRING and relating to infection are highlighted (see colour code included in the figure). (C) KEGG pathways relating to the identified proteins and reported in STRING are highlighted for immunity (see colour code included in the figure). (D) KEGG pathways relating to cancer and disease for deiminated proteins identified are highlighted for (see colour code included in the figure). (E) KEEG pathways relating to metabolism for deiminated proteins identified are highlighted (see colour code included in the figure). The coloured lines highlight which protein interactions are identified through known interactions (this refers to curated databases, experimentally determined), through predicted interactions (this refers to gene neighborhood, gene fusion, gene co-occurrence) or through co-expression, text mining or protein homology (the colour key for connective lines is included in the figure).